CICADAS and then PEERS for Autism Spectrum Disorder

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Autism Spectrum Disorder+2 More
CICADAS and then PEERS - Other
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing an app to help improve social-emotional learning for adolescents on the autism spectrum.

Eligible Conditions
  • Autism Spectrum Disorder
  • Autism Spectrum Disorders

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Autism Spectrum Disorder

Study Objectives

5 Primary · 0 Secondary · Reporting Duration: 16 weeks

16 weeks
Digital Assessment Completion Rate
NB-SCT Program Adherence
Post-Study Usability Ratings
Reported Number of Adverse Effects
Total number of participants who complete the intervention

Trial Safety

Safety Progress

1 of 3

Other trials for Autism Spectrum Disorder

Trial Design

3 Treatment Groups

Arm C
1 of 3
Arm A
1 of 3
Arm B
1 of 3
Experimental Treatment

48 Total Participants · 3 Treatment Groups

Primary Treatment: CICADAS and then PEERS · No Placebo Group · N/A

Arm C
Other
Experimental Group · 1 Intervention: PEERS + Active Comparator and then no-contact · Intervention Types: Other
Arm A
Other
Experimental Group · 1 Intervention: CICADAS and then PEERS · Intervention Types: Other
Arm B
Other
Experimental Group · 1 Intervention: PEERS + CICADAS and then no-contact · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 16 weeks

Who is running the clinical trial?

University of MinnesotaOTHER
1,239 Previous Clinical Trials
1,460,630 Total Patients Enrolled
5 Trials studying Autism Spectrum Disorder
131 Patients Enrolled for Autism Spectrum Disorder
Posit Science CorporationLead Sponsor
38 Previous Clinical Trials
4,149 Total Patients Enrolled
Bruno Biagianti, MDPrincipal InvestigatorPosit Science Corporation
1 Previous Clinical Trials
34 Total Patients Enrolled
Kyu Lee, PhDPrincipal InvestigatorPosit Science Corporation
2 Previous Clinical Trials
172 Total Patients Enrolled

Eligibility Criteria

Age < 65 · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
The potential participant has an IQ score above 70 on the Wechsler Abbreviated Scale of Intelligence or a comparable measure in medical or clinical records.
The potential participant has normal vision or better; this was either self-reported or reported by a parent.
The potential participant is a fluent English speaker, based on the participant's or the parent/legal guardian's self-report, and this is confirmed by the screening clinician to ensure that the participant's neuropsychological results will be reasonable.
The potential participant has the necessary sensorimotor skills to be able to participate in and complete the study activities, including having good vision to be able to read from a computer screen or mobile device at a normal viewing distance, good hearing to be able to understand normal speech, and good motor skills to be able to control and use a mobile device and/or computer
Potential participants must be between the age of 11 and 18 in order to consent.
The potential participant has a clinical diagnosis of Autism Spectrum Disorder, as confirmed by medical/clinical records or standardized assessments/interviews.
The person who participates in this study must be clinically stable due to a therapeutic or medication regimen for the past 4 weeks.
The potential participant has regular and reliable access to the internet.
The potential participant has normal hearing, as reported by themselves or their parent.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: October 5th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
Pennsylvania66.7%
New York33.3%
How old are they?
18 - 65100.0%
What site did they apply to?
University of Minnesota100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%